Quick Answer
Silexion Therapeutics Corp reported Net Income of -$11.91 million for fiscal year 2025.
Silexion Therapeutics Corp Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$11.91M | +27.9% |
| 2024 | -$16.52M | -223.4% |
| 2023 | -$5.11M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.26M | +72.5% | -30.3% |
| June 30, 2025 | -$2.50M | -68.1% | -44.3% |
| March 31, 2025 | -$1.74M | -21.9% | +85.4% |
| September 30, 2024 | -$11.86M | -1366.0% | -696.5% |
| June 30, 2024 | -$1.49M | +20.6% | -4.6% |
| March 31, 2024 | -$1.42M | — | -75.9% |
| September 30, 2023 | -$809.0K | — | +56.9% |
| June 30, 2023 | -$1.88M | — | — |
- Silexion Therapeutics Corp showed an increase of +27.9% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, Silexion Therapeutics Corp’s net income has declined by 133.2% (from -$5.11 million to -$11.91 million).
- The most recent figure is from Silexion Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: